A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

Summary

This trial adopts a multicenter, open label, positive drug parallel controlled clinical trial design, with a planned enrollment of approximately 105 participants in the MF trial. Successful trial participants were selected and assigned to either the experimental group or the control group in a 2:1 stratified manner, with the stratification factor being the Dynamic International Prognostic Scoring System (DIPSS) prognostic grading criteria. Continuously take the test drug/control drug until it meets the withdrawal criteria.

Timeline

Start

2026-02-13

Primary completion

2027-12-30

Completion

2028-03-30

Drugs

Indications

No indication recorded.